



Press release from Emotra AB (publ)
Göteborg, March 12, 2014

Emotra has CE marked EDOR

Emotra is proud to announce that our EDOR system is now CE marked. This marking is an important milestone in the preparations of our planned international, multi-centre clinical trials.

We have been working to secure a CE marking of our product since the summer of 2013. This work has encompassed the development of a relevant quality-assurance system as well as assembling both technical and clinical, product-related and method-related documentation. The CE marking is a confirmation that Emotra's product and documentation comply with the Medical Device Directive.

Securing this CE marking has been an important condition for the Company's ability to initiate its extensive, international, multi-centre, clinical trials. Consequently, we will be conducting training/kick-off meetings in the near future. The individual clinics involved will be able to start testing patients as soon as their respective ethical committees have given the green light.

So far, fourteen clinics have signed co-operation agreements with Emotra. Our aim is to engage at least 15 European clinics in the trials of Emotra's testing method, EDOR. These trials are planned to take place during the coming two years. We are presently discussing and negotiating with several clinics in various countries.

Emotra has entered a dynamic phase with an increasing number of collaboration clinics. In this phase, the Company is being run with a skeleton crew and as cost-effectively as possible in order not to jeopardise its long-term financial health. Once Emotra's method has received sufficiently strong scientific backing from the clinics evaluating EDOR, we will initiate a launch of the method in Europe.

For further information, please contact:

Claes Holmberg, CEO

Telephone: +46 708 25 45 47

E-mail: claes@emotra.se

Emotra AB is listed on AktieTorget, and the Company has developed a method – EDOR – of detecting depressed patients who are at risk of committing suicide. Altogether, more than 1,000 patients have been tested and followed up. EDOR has shown a reliability rate of up to 97%. In other words, Emotra's method can determine, with 97% certainty, if a person runs a significantly higher risk of suicide attempt, facilitating decisions about where special suicide prevention measures are needed. EDOR helps the right patients get the care they need.